Sequoiacrone
August 23rd, 2008, 12:25 PM
Cardiovascular effects of Cannabis:
5.1 Cannabis increases heart rate in na•ve users although tolerance develops to this effect.
5.2 Cannabinoids can also reduce blood pressure via arteriollar dilatation in a variety of tissues, although the effect on blood flow varies at a local level, with some organs or brain regions experiencing vasoconstriction, others vasodilation.
5.3 In the withdrawal phase following cessation of chronic use, cerebral blood flow may be significantly reduced.
5.4 Cannabis use has been implicated as a causative factor in a small number of patients suffering strokes or transient ischaemic attacks, and may represent a risk factor to susceptible individuals.
5.5 However cannabinoids, in particular CB1-receptor agonists, have been shown to protect against nerve cell death following stroke, and dexanabinol at an advanced stage of the licensing process as a drug to be administered to victims of stroke or closed-head injuries to minimise the long-term brain damage caused by such events, and to improve survival and recovery prospects
To read more and in particular a number of research studies and resouces at the bottom of the page and the contributor to those studies see here
http://www.idmu.co.uk/canncardio.htm
5.1 Cannabis increases heart rate in na•ve users although tolerance develops to this effect.
5.2 Cannabinoids can also reduce blood pressure via arteriollar dilatation in a variety of tissues, although the effect on blood flow varies at a local level, with some organs or brain regions experiencing vasoconstriction, others vasodilation.
5.3 In the withdrawal phase following cessation of chronic use, cerebral blood flow may be significantly reduced.
5.4 Cannabis use has been implicated as a causative factor in a small number of patients suffering strokes or transient ischaemic attacks, and may represent a risk factor to susceptible individuals.
5.5 However cannabinoids, in particular CB1-receptor agonists, have been shown to protect against nerve cell death following stroke, and dexanabinol at an advanced stage of the licensing process as a drug to be administered to victims of stroke or closed-head injuries to minimise the long-term brain damage caused by such events, and to improve survival and recovery prospects
To read more and in particular a number of research studies and resouces at the bottom of the page and the contributor to those studies see here
http://www.idmu.co.uk/canncardio.htm